Literature DB >> 28533077

Medical management of claudication.

Elizabeth V Ratchford1.   

Abstract

Peripheral artery disease (PAD) is common and associated with significant morbidity and mortality. Optimal medical management of PAD is required for each patient, irrespective of the decision regarding lower extremity revascularization. The goals include reducing cardiovascular morbidity and mortality and improving quality of life. The approach should consist of aggressive and individualized risk factor modification including smoking cessation, antiplatelet therapy, a statin, and an angiotensin-converting enzyme inhibitor. Exercise is critical for cardiovascular health and highly effective for improving claudication symptoms. Cilostazol may be considered for symptomatic treatment in certain patients.
Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28533077     DOI: 10.1016/j.jvs.2017.02.040

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  3 in total

1.  A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.

Authors:  Kerry S Russell; Denise P Yates; Christopher M Kramer; Andrea Feller; Ping Mahling; Laurence Colin; Timothy Clough; Tianke Wang; Lucy LaPerna; Alpa Patel; Holger Lawall; Mustafa M Shennak; James Fulmer; Sigrid Nikol; William B Smith; Oliver J Müller; Elizabeth V Ratchford; Craig T Basson
Journal:  Vasc Med       Date:  2019-07-05       Impact factor: 3.239

Review 2.  Treatment Strategies for the Claudicant.

Authors:  Keith Pereira
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

3.  Cilostazol protects hepatocytes against alcohol-induced apoptosis via activation of AMPK pathway.

Authors:  Youn Ju Lee; Mi-Sun Shu; Jong-Yeon Kim; Yun-Hye Kim; Kyeong Hwa Sim; Woo Jung Sung; Jong Ryeol Eun
Journal:  PLoS One       Date:  2019-01-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.